Qi Xiao-Ping, Lian Bi-Jun, Fang Xu-Dong, Dong Fang, Li Feng, Jin Hang-Yang, Zhang Ke, Wang Kang-Er, Zhang Yi
Department of Oncologic and Urologic Surgery, The 903rd PLA Hospital, Hangzhou Medical College, Hangzhou, China.
Center for Radiation Oncology, Affiliated Hangzhou Cancer Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Front Surg. 2023 Jan 10;9:1057821. doi: 10.3389/fsurg.2022.1057821. eCollection 2022.
This study aimed to assess the feasibility of synchronous bilateral laparoscopic or open cortical-sparing adrenalectomy (SB-LCSA or SB-OCSA) for bilateral pheochromocytomas (bPHEOs) in multiple endocrine neoplasia type 2 (MEN2).
Altogether, 31 patients (54.8% were women) were diagnosed with MEN2-related bPHEOs, and 29 of them underwent varying specific adrenalectomies. We systematically analyzed and evaluated their clinical profiles, mutation types, tumor histopathological features, and follow-up records.
All 31 patients with bPHEOs presented with -C634 (90.3%) and -M918T (9.7%) mutations, and the median age at initial presentation was 38 years (range, 23-78). bPHEOs were synchronous in 27 patients and metachronous in 4 (12.9%) patients. In total, 29 patients underwent initial cortical-sparing adrenalectomy (CSA) including 23 (79.3%) undergoing synchronous bilateral CSA (18 SB-LCSA and 5 SB-OCSA) and 6 (20.7%) undergoing metachronous CSA. SB-LCSA and synchronous surgery were associated with less bleeding volume and shorter length of hospital stay than SB-OCSA and metachronous surgery (all 's < 0.05). Corticosteroid replacement treatment was necessary for 14 patients (45.2%) after bilateral CSA. During a median follow-up period of 7 years (range, 1.8-23), three of these patients (10.3%) had a recurrent disease that required reoperation.
SB-LCSA is feasible for treating synchronous bPHEOs and should be recommended as a prioritized surgical approach.
本研究旨在评估同步双侧腹腔镜或开放性保留肾上腺皮质切除术(SB-LCSA或SB-OCSA)治疗2型多发性内分泌腺瘤病(MEN2)相关双侧嗜铬细胞瘤(bPHEO)的可行性。
共有31例患者(54.8%为女性)被诊断为MEN2相关bPHEO,其中29例接受了不同的特定肾上腺切除术。我们系统分析并评估了他们的临床资料、突变类型、肿瘤组织病理学特征及随访记录。
31例bPHEO患者均存在-C634(90.3%)和-M918T(9.7%)突变,初次就诊时的中位年龄为38岁(范围23-78岁)。27例患者的bPHEO为同步发生,4例(12.9%)为异时发生。共有29例患者接受了初次保留肾上腺皮质切除术(CSA),其中23例(79.3%)接受同步双侧CSA(18例SB-LCSA和5例SB-OCSA),6例(20.7%)接受异时CSA。与SB-OCSA和异时手术相比,SB-LCSA和同步手术的出血量更少,住院时间更短(所有P值均<0.05)。双侧CSA后,14例患者(45.2%)需要进行皮质类固醇替代治疗。在中位随访期7年(范围1.8-23年)内,这些患者中有3例(10.3%)疾病复发,需要再次手术。
SB-LCSA治疗同步性bPHEO是可行的,应作为优先推荐的手术方式。